Bostan, H. Et Al. 2020. Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.. Clinical lymphoma, myeloma & leukemia , vol.20, no.12 , 836-842.

Bostan, H., Toptas, T., Tanrikulu, F., Kut, K., Arikan, F., Yilmaz, F., ... Atagunduz, I.(2020). Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.. Clinical lymphoma, myeloma & leukemia , vol.20, no.12, 836-842.

Bostan, Hayri Et Al. "Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.," Clinical lymphoma, myeloma & leukemia , vol.20, no.12, 836-842, 2020

Bostan, Hayri Et Al. "Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.." Clinical lymphoma, myeloma & leukemia , vol.20, no.12, pp.836-842, 2020

Bostan, H. Et Al. (2020) . "Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.." Clinical lymphoma, myeloma & leukemia , vol.20, no.12, pp.836-842.

@article{article, author={Hayri Bostan Et Al. }, title={Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.}, journal={Clinical lymphoma, myeloma & leukemia}, year=2020, pages={836-842} }